Aβ
42 programs · 41 companies
Programs
42
Companies
41
Active Trials
26
Targeting Aβ
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Asthma | |
| Sotovorutinib | Pfizer | Approved | MDS | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | PsA | |
| Datobrutinib | Sanofi | Phase 3 | FTDEpilepsy | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | ACCMS | |
| VRT-5853 | Vertex Pharma | Phase 3 | NarcolepsyAML | |
| ARG-314 | Argenx | Approved | Endometrial Ca | |
| BMR-9762 | BioMarin | Phase 3 | Psoriasis | |
| NBI-3153 | Neurocrine | Approved | Bladder Ca | |
| Geliglumide | Samsung Biologics | Phase 1 | OCDACC | |
| PST-2276 | Poseida | Approved | CMLUC | |
| 452-7432 | Ono Pharma | Phase 2 | Huntington'sGastric Ca | |
| 187-151 | Shanghai Junshi | Phase 1 | ALSAS | |
| Nidaosocimab | Mesoblast | Preclinical | ALLOvarian Ca | |
| MD-IIT-802 | MD Anderson | Phase 2/3 | MG | |
| DAN-IIT-236 | Dana-Farber | Preclinical | Urothelial Ca | |
| ATH-2491 | Athira Pharma | Approved | CSU | |
| CN-8014 | CN Bio Innovations | Phase 2/3 | CLLWilms | |
| Voxavorutinib | Puma Biotech | Phase 2 | WMNarcolepsy | |
| INB-9118 | Inhibrx Biosciences | Phase 3 | Parkinson's | |
| Peminaritide | Shire (Takeda) | Phase 1/2 | Cervical Ca | |
| Motabrutinib | Proteon (Charles River) | Preclinical | UC | |
| Rimavorutinib | CSPC Pharma | Phase 2 | LN | |
| PHA-9567 | Phathom Pharma | Phase 2/3 | IPF | |
| CUR-8000 | Curocell | Phase 2 | Ewing SarcomaRSV | |
| 174-8981 | Abclon | Phase 2 | OCDMS | |
| Motanaritide | Clinigen | NDA/BLA | Cervical CaAS | |
| Talatinib | Immunicum | Phase 2 | DMDFSGS | |
| VAL-4454 | Valneva | Preclinical | NBMCC | |
| BWA-1517 | Brainsway | Approved | FTDRSV | |
| MYG-2072 | Myriad Genetics | Phase 2 | MesoBCC | |
| XER-568 | Xeris Biopharma | Phase 1 | PsoriasisAML | |
| Gelicapivasertib | Lundbeck | Approved | Epilepsy | |
| ORN-2989 | Orion Pharma | Phase 1 | MyelofibrosisDMD | |
| Datocagene | IPCA Labs | Phase 2 | SCLCIgAN | |
| AAR-3535 | Aarti Drugs | Phase 3 | SCD | |
| Doxacapivasertib | Wockhardt | Phase 2/3 | HSPBC | |
| Mirisacituzumab | Teva Pharma | Phase 2 | Asthma | |
| WES-IIT-392 | West China Hosp | Phase 1 | T2D | |
| AII-IIT-336 | AIIMS New Delhi | Preclinical | NB | |
| Rilunaritide | MSN Laboratories | Phase 1 | FTDPNH | |
| Polasertib | Bioceres Crop | Phase 1/2 | Bladder Ca |